Bank of New York Mellon Corp Has $2.87 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Bank of New York Mellon Corp lowered its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 3.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 208,396 shares of the company’s stock after selling 6,987 shares during the period. Bank of New York Mellon Corp owned approximately 0.24% of Day One Biopharmaceuticals worth $2,872,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quest Partners LLC acquired a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. increased its position in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after buying an additional 1,000 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Day One Biopharmaceuticals during the second quarter worth $113,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth $156,000. Finally, SteelPeak Wealth LLC acquired a new stake in Day One Biopharmaceuticals in the second quarter worth $218,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the sale, the insider now owns 1,127,535 shares in the company, valued at $15,785,490. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the completion of the transaction, the insider now owns 1,127,535 shares of the company’s stock, valued at $15,785,490. The disclosure for this sale can be found here. Insiders sold a total of 78,748 shares of company stock valued at $1,141,172 in the last three months. 8.40% of the stock is currently owned by corporate insiders.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN opened at $14.13 on Monday. The firm’s 50-day moving average price is $14.35 and its 200-day moving average price is $14.61. The company has a market capitalization of $1.23 billion, a PE ratio of -5.63 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 1-year low of $9.67 and a 1-year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million. Equities analysts anticipate that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DAWN shares. JPMorgan Chase & Co. dropped their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Bank of America raised shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, July 30th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.